JP2019531274A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531274A5 JP2019531274A5 JP2019511947A JP2019511947A JP2019531274A5 JP 2019531274 A5 JP2019531274 A5 JP 2019531274A5 JP 2019511947 A JP2019511947 A JP 2019511947A JP 2019511947 A JP2019511947 A JP 2019511947A JP 2019531274 A5 JP2019531274 A5 JP 2019531274A5
- Authority
- JP
- Japan
- Prior art keywords
- bis
- oxy
- biphenyl
- dimethyl
- diyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 amino, carboxy Chemical group 0.000 claims 187
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 83
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 64
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 52
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 claims 46
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 28
- 235000010290 biphenyl Nutrition 0.000 claims 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 22
- 125000004076 pyridyl group Chemical group 0.000 claims 21
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 20
- 125000005843 halogen group Chemical group 0.000 claims 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 14
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000003386 piperidinyl group Chemical group 0.000 claims 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 229940124597 therapeutic agent Drugs 0.000 claims 11
- 239000004146 Propane-1,2-diol Substances 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims 10
- 229960004063 propylene glycol Drugs 0.000 claims 10
- 235000013772 propylene glycol Nutrition 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 9
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 claims 8
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 claims 8
- DBXBTMSZEOQQDU-UHFFFAOYSA-N 3-hydroxyisobutyric acid Chemical compound OCC(C)C(O)=O DBXBTMSZEOQQDU-UHFFFAOYSA-N 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 6
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000002883 imidazolyl group Chemical group 0.000 claims 5
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 5
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 4
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 claims 4
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 claims 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 4
- 125000004450 alkenylene group Chemical group 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 3
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 235000019260 propionic acid Nutrition 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- UXOQCYFKGDPUDV-PLXFJCCSSA-N (2S,4R)-4-hydroxy-1-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidine-2-carboxylic acid Chemical compound O[C@@H]1C[C@H](N(C1)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C)C(=O)O UXOQCYFKGDPUDV-PLXFJCCSSA-N 0.000 claims 2
- PKCXYIGMQIXBHG-YOQGVNIDSA-N (3R)-1-[3-[3-[3-[2-[(3R)-3-hydroxypyrrolidin-1-yl]ethyl]-2,3-dihydro-1,4-benzodioxin-6-yl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound O[C@H]1CN(CC1)CCC1OC2=C(OC1)C=CC(=C2)C=1C(=C(OCCCN2C[C@@H](CC2)O)C=CC=1)C PKCXYIGMQIXBHG-YOQGVNIDSA-N 0.000 claims 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical group C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 2
- SPJPZSUFBQISRE-UHFFFAOYSA-N 1-[3-[2-methyl-3-(2-methylphenyl)phenoxy]propyl]pyrrolidin-3-ol Chemical compound OC1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C=CC=C1)C)C SPJPZSUFBQISRE-UHFFFAOYSA-N 0.000 claims 2
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N 4-hydroxyproline Chemical compound OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims 2
- FGKJLKRYENPLQH-UHFFFAOYSA-N isocaproic acid Chemical compound CC(C)CCC(O)=O FGKJLKRYENPLQH-UHFFFAOYSA-N 0.000 claims 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims 2
- BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 claims 2
- BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 claims 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- ZAMUNOUDPJRWIJ-QPPBQGQZSA-N (2S)-2-hydroxy-3-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propylamino]propanoic acid Chemical compound O[C@H](C(=O)O)CNCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C ZAMUNOUDPJRWIJ-QPPBQGQZSA-N 0.000 claims 1
- SHMLWSKIQITORU-VMPREFPWSA-N (2S)-3-[3-[3-[3-[3-[[(2S)-2,3-dihydroxypropyl]-(2-pyridin-3-ylethyl)amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propylamino]propane-1,2-diol Chemical compound O[C@@H](CN(CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCNC[C@@H](CO)O)C)C)CCC=1C=NC=CC=1)CO SHMLWSKIQITORU-VMPREFPWSA-N 0.000 claims 1
- XUVCRLNALYWPFO-DFHRPNOPSA-N (2S)-3-hydroxy-2-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propylamino]-2-methylpropanoic acid Chemical compound OC[C@](C(=O)O)(C)NCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C XUVCRLNALYWPFO-DFHRPNOPSA-N 0.000 claims 1
- IQYCVHPCIZMJIG-JUQKIHQQSA-N (2S,3S)-3-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propylamino]-3-phenylpropane-1,2-diol Chemical compound O[C@H]1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN[C@H]([C@@H](CO)O)C1=CC=CC=C1)C)C IQYCVHPCIZMJIG-JUQKIHQQSA-N 0.000 claims 1
- SPJPZSUFBQISRE-GOSISDBHSA-N (3R)-1-[3-[2-methyl-3-(2-methylphenyl)phenoxy]propyl]pyrrolidin-3-ol Chemical compound O[C@H]1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C=CC=C1)C)C SPJPZSUFBQISRE-GOSISDBHSA-N 0.000 claims 1
- PJFDIUZZYNDMBT-RUZDIDTESA-N (3R)-1-[3-[2-methyl-3-[2-methyl-3-(3-piperidin-1-ylpropoxy)phenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=C(C(=CC=C1)OCCCN1CCCCC1)C PJFDIUZZYNDMBT-RUZDIDTESA-N 0.000 claims 1
- UTWZLLUIGZQEHS-XMMISQBUSA-N (3R)-1-[3-[2-methyl-3-[2-methyl-3-[(1-methylpiperidin-3-yl)methoxy]phenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=C(C(=CC=C1)OCC1CN(CCC1)C)C UTWZLLUIGZQEHS-XMMISQBUSA-N 0.000 claims 1
- AOTXMUNSPVUYKX-RUZDIDTESA-N (3R)-1-[3-[2-methyl-3-[2-methyl-3-[3-(2-pyrazol-1-ylethylamino)propoxy]phenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound N1(N=CC=C1)CCNCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C AOTXMUNSPVUYKX-RUZDIDTESA-N 0.000 claims 1
- YFWBKLCOKIURAV-GDLZYMKVSA-N (3R)-1-[3-[2-methyl-3-[2-methyl-3-[3-[methyl(2-phenylethyl)amino]propoxy]phenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=C(C(=CC=C1)OCCCN(CCC1=CC=CC=C1)C)C YFWBKLCOKIURAV-GDLZYMKVSA-N 0.000 claims 1
- IUYQJMVGGQCYAW-HHHXNRCGSA-N (3R)-1-[3-[2-methyl-3-[2-methyl-3-[3-[methyl(pyridin-2-ylmethyl)amino]propoxy]phenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=C(C(=CC=C1)OCCCN(CC1=NC=CC=C1)C)C IUYQJMVGGQCYAW-HHHXNRCGSA-N 0.000 claims 1
- ZMDHASBCNOHLFM-HHHXNRCGSA-N (3R)-1-[3-[2-methyl-3-[2-methyl-3-[3-[methyl(pyridin-4-ylmethyl)amino]propoxy]phenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=C(C(=CC=C1)OCCCN(CC1=CC=NC=C1)C)C ZMDHASBCNOHLFM-HHHXNRCGSA-N 0.000 claims 1
- JCMVCJJPQVNXSQ-AREMUKBSSA-N (3R)-1-[3-[2-methyl-3-[2-methyl-3-[3-[methyl-[2-[2-(methylamino)ethoxy]ethyl]amino]propoxy]phenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=C(C(=CC=C1)OCCCN(CCOCCNC)C)C JCMVCJJPQVNXSQ-AREMUKBSSA-N 0.000 claims 1
- UDCOHOFRJVUEGM-AREMUKBSSA-N (3R)-1-[3-[2-methyl-3-[3-(3-phenylpropoxy)phenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=CC(=CC=C1)OCCCC1=CC=CC=C1 UDCOHOFRJVUEGM-AREMUKBSSA-N 0.000 claims 1
- YHEYJBXAADEELQ-FGZHOGPDSA-N (3R)-1-[3-[3-[2-chloro-3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]phenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound ClC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C YHEYJBXAADEELQ-FGZHOGPDSA-N 0.000 claims 1
- VSJTZCLPKHRPRH-AREMUKBSSA-N (3R)-1-[3-[3-[3-[3-(3-imidazol-1-ylpropylamino)propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound N1(C=NC=C1)CCCNCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C VSJTZCLPKHRPRH-AREMUKBSSA-N 0.000 claims 1
- ZVPPJPUZOIVUTB-GDLZYMKVSA-N (3R)-1-[3-[3-[3-[3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound COC=1C=C2CCN(CC2=CC=1OC)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C ZVPPJPUZOIVUTB-GDLZYMKVSA-N 0.000 claims 1
- XNPYNCNECHZDJZ-QZWVJJBASA-N (3R)-1-[3-[3-[3-[3-[(2-hydroxy-1-pyridin-4-ylethyl)amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound OCC(C1=CC=NC=C1)NCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C XNPYNCNECHZDJZ-QZWVJJBASA-N 0.000 claims 1
- BNNLKLMGJWJKAC-QZWVJJBASA-N (3R)-1-[3-[3-[3-[3-[(2-hydroxy-2-pyridin-3-ylethyl)amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound OC(CNCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C)C=1C=NC=CC=1 BNNLKLMGJWJKAC-QZWVJJBASA-N 0.000 claims 1
- FNOQQPWACKVFEW-DNQXCXABSA-N (3R)-1-[3-[3-[3-[3-[(3R)-3-fluoropyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound F[C@H]1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C FNOQQPWACKVFEW-DNQXCXABSA-N 0.000 claims 1
- IYMILTTVAXIHRW-JWQCQUIFSA-N (3R)-1-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]piperidine-3-carboxylic acid Chemical compound O[C@H]1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CCC1)C(=O)O)C)C IYMILTTVAXIHRW-JWQCQUIFSA-N 0.000 claims 1
- HPXNLRDTKCJCDZ-DNQXCXABSA-N (3R)-1-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C HPXNLRDTKCJCDZ-DNQXCXABSA-N 0.000 claims 1
- IXHPUSSTLKYZHV-DNQXCXABSA-N (3R)-1-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-4-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=CC(=CC=C1C)OCCCN1C[C@@H](CC1)O IXHPUSSTLKYZHV-DNQXCXABSA-N 0.000 claims 1
- VTJJWWVIJXQBIQ-DNQXCXABSA-N (3R)-1-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=CC(=CC=C1)OCCCN1C[C@@H](CC1)O VTJJWWVIJXQBIQ-DNQXCXABSA-N 0.000 claims 1
- IEZQRFAPDCUVGU-RUZDIDTESA-N (3R)-1-[3-[3-[3-[3-[2-(4-chloropyrazol-1-yl)ethylamino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound ClC=1C=NN(C=1)CCNCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C IEZQRFAPDCUVGU-RUZDIDTESA-N 0.000 claims 1
- CYNGYKDELPIQQQ-OFSOJUDTSA-N (3R)-1-[3-[3-[3-[3-[[(1R)-2-hydroxy-1-phenylethyl]amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound OC[C@@H](C1=CC=CC=C1)NCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C CYNGYKDELPIQQQ-OFSOJUDTSA-N 0.000 claims 1
- CYNGYKDELPIQQQ-POURPWNDSA-N (3R)-1-[3-[3-[3-[3-[[(1S)-2-hydroxy-1-phenylethyl]amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound OC[C@H](C1=CC=CC=C1)NCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C CYNGYKDELPIQQQ-POURPWNDSA-N 0.000 claims 1
- CMCZELPZYAAQHT-OFSOJUDTSA-N (3R)-1-[3-[3-[3-[3-[[(2R)-2-hydroxy-2-phenylethyl]amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound O[C@@H](CNCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C)C1=CC=CC=C1 CMCZELPZYAAQHT-OFSOJUDTSA-N 0.000 claims 1
- IIPCFTKEDHLOME-FYBSXPHGSA-N (3R)-1-[3-[3-[3-[3-[[(2S)-2-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound ClC=1C=C(C=CC=1F)[C@@H](CNCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C)O IIPCFTKEDHLOME-FYBSXPHGSA-N 0.000 claims 1
- CMCZELPZYAAQHT-POURPWNDSA-N (3R)-1-[3-[3-[3-[3-[[(2S)-2-hydroxy-2-phenylethyl]amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound O[C@H](CNCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C)C1=CC=CC=C1 CMCZELPZYAAQHT-POURPWNDSA-N 0.000 claims 1
- NUBHGLMREPGLGL-HHHXNRCGSA-N (3R)-1-[3-[3-[3-[3-[[1-(2-hydroxyethyl)piperidin-4-yl]amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound OCCN1CCC(CC1)NCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C NUBHGLMREPGLGL-HHHXNRCGSA-N 0.000 claims 1
- ADSFSZYYGNVUHL-GDLZYMKVSA-N (3R)-1-[3-[3-[3-[3-[benzyl(2-hydroxyethyl)amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound C(C1=CC=CC=C1)N(CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C)CCO ADSFSZYYGNVUHL-GDLZYMKVSA-N 0.000 claims 1
- BUGJYGHQJSWDBX-DNQXCXABSA-N (3R)-1-[3-[4-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-3-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=C(C=C(C=C1)OCCCN1C[C@@H](CC1)O)C BUGJYGHQJSWDBX-DNQXCXABSA-N 0.000 claims 1
- FCCSWLNEJMUTJO-DNQXCXABSA-N (3R)-1-[3-[4-[4-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-3-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC(=C1)OCCCN1C[C@@H](CC1)O)C1=C(C=C(C=C1)OCCCN1C[C@@H](CC1)O)C FCCSWLNEJMUTJO-DNQXCXABSA-N 0.000 claims 1
- WUSFFJIDDPAQHQ-JWQCQUIFSA-N (3R)-1-[4-[3-[4-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]butyl]pyrrolidin-3-ol Chemical compound O[C@H]1CN(CC1)CCCCOC=1C(=C(C=CC=1)C1=C(C=C(C=C1)OCCCN1C[C@@H](CC1)O)C)C WUSFFJIDDPAQHQ-JWQCQUIFSA-N 0.000 claims 1
- WUVNULDMRXFGDS-CLJLJLNGSA-N (3R)-1-[5-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]pentyl]pyrrolidin-3-ol Chemical compound O[C@H]1CN(CC1)CCCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C WUVNULDMRXFGDS-CLJLJLNGSA-N 0.000 claims 1
- KBELCPHWNGPHOG-CLJLJLNGSA-N (3R)-1-[5-[3-[4-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]pentyl]pyrrolidin-3-ol Chemical compound O[C@H]1CN(CC1)CCCCCOC=1C(=C(C=CC=1)C1=C(C=C(C=C1)OCCCN1C[C@@H](CC1)O)C)C KBELCPHWNGPHOG-CLJLJLNGSA-N 0.000 claims 1
- UBJPXBZEZGDPQH-NGDRWEMDSA-N (3S)-1-[3-[2-[3-[(3S)-3-hydroxypyrrolidin-1-yl]propoxy]-4-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound O[C@H]1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=CC(=C(C=C1)OCCCN1C[C@H](CC1)O)OCCCN1C[C@H](CC1)O)C UBJPXBZEZGDPQH-NGDRWEMDSA-N 0.000 claims 1
- GYYVGEMSSWKNMD-UIOOFZCWSA-N (3S)-1-[3-[3-[3-[3-[(3S)-3-carboxypiperidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]piperidine-3-carboxylic acid Chemical compound CC1=C(C=CC=C1OCCCN1C[C@H](CCC1)C(=O)O)C1=C(C(=CC=C1)OCCCN1C[C@H](CCC1)C(=O)O)C GYYVGEMSSWKNMD-UIOOFZCWSA-N 0.000 claims 1
- YSTRONQQJNRDRP-INNMJMHTSA-N (3S,4R)-4-(hydroxymethyl)-1-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]piperidin-3-ol Chemical compound OC[C@@H]1[C@@H](CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C)O YSTRONQQJNRDRP-INNMJMHTSA-N 0.000 claims 1
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 claims 1
- FBCPPJXBGRDJGH-DHIUTWEWSA-N 1-[2-[(3R)-3-hydroxypyrrolidin-1-yl]ethyl]-3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenyl]urea Chemical compound O[C@H]1CN(CC1)CCNC(=O)NC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C FBCPPJXBGRDJGH-DHIUTWEWSA-N 0.000 claims 1
- IYHHWMYWNOFUKT-UHFFFAOYSA-N 1-[3-[3-[3-[3-(4-carboxy-4-hydroxypiperidin-1-yl)propoxy]-2-chlorophenyl]-2-methylphenoxy]propyl]-4-hydroxypiperidine-4-carboxylic acid Chemical compound ClC1=C(C=CC=C1OCCCN1CCC(CC1)(C(=O)O)O)C1=C(C(=CC=C1)OCCCN1CCC(CC1)(C(=O)O)O)C IYHHWMYWNOFUKT-UHFFFAOYSA-N 0.000 claims 1
- GCVPODDPVKJAFV-UHFFFAOYSA-N 1-[3-[3-[3-[3-[(2,3-dihydroxy-3-methylbutyl)amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propylamino]-3-methylbutane-2,3-diol Chemical compound CC1=C(C=CC=C1OCCCNCC(C(C)(O)C)O)C1=C(C(=CC=C1)OCCCNCC(C(C)(O)C)O)C GCVPODDPVKJAFV-UHFFFAOYSA-N 0.000 claims 1
- LULCOUVAHYGRRH-UHFFFAOYSA-N 1-[3-[3-[3-[3-[(2-hydroxy-3-methoxypropyl)amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propylamino]-3-methoxypropan-2-ol Chemical compound CC1=C(C=CC=C1OCCCNCC(COC)O)C1=C(C(=CC=C1)OCCCNCC(COC)O)C LULCOUVAHYGRRH-UHFFFAOYSA-N 0.000 claims 1
- MEEQKUPPZLMINN-UHFFFAOYSA-N 1-[3-[3-[3-[3-[3-(dimethylamino)azetidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]-N,N-dimethylazetidin-3-amine Chemical compound CC1=C(C=CC=C1OCCCN1CC(C1)N(C)C)C1=C(C(=CC=C1)OCCCN1CC(C1)N(C)C)C MEEQKUPPZLMINN-UHFFFAOYSA-N 0.000 claims 1
- PKVXYGUTVSNABO-UHFFFAOYSA-N 1-[5-chloro-4-[[3-[3-[[2-chloro-5-methoxy-4-[(1,3-thiazol-5-ylmethylamino)methyl]phenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-2-methoxyphenyl]-N-(1,3-thiazol-5-ylmethyl)methanamine Chemical compound CC1=C(C=CC=C1COC1=CC(=C(C=C1Cl)CNCC1=CN=CS1)OC)C1=C(C(=CC=C1)COC1=CC(=C(C=C1Cl)CNCC1=CN=CS1)OC)C PKVXYGUTVSNABO-UHFFFAOYSA-N 0.000 claims 1
- OQLJKWTXDSBBGZ-UHFFFAOYSA-N 1-[5-chloro-4-[[3-[3-[[2-chloro-5-methoxy-4-[(pyrimidin-5-ylmethylamino)methyl]phenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-2-methoxyphenyl]-N-(pyrimidin-5-ylmethyl)methanamine Chemical compound CC1=C(C=CC=C1COC1=CC(=C(C=C1Cl)CNCC=1C=NC=NC=1)OC)C1=C(C(=CC=C1)COC1=CC(=C(C=C1Cl)CNCC=1C=NC=NC=1)OC)C OQLJKWTXDSBBGZ-UHFFFAOYSA-N 0.000 claims 1
- AHLVPOIIVXTDQO-UHFFFAOYSA-N 1-[5-chloro-4-[[3-[3-[[2-chloro-5-methoxy-4-[[methyl(1,3-thiazol-5-ylmethyl)amino]methyl]phenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-2-methoxyphenyl]-N-methyl-N-(1,3-thiazol-5-ylmethyl)methanamine Chemical compound CC1=C(C=CC=C1COC1=CC(=C(C=C1Cl)CN(C)CC1=CN=CS1)OC)C1=C(C(=CC=C1)COC1=CC(=C(C=C1Cl)CN(CC1=CN=CS1)C)OC)C AHLVPOIIVXTDQO-UHFFFAOYSA-N 0.000 claims 1
- VYBHXDNJGRZXKI-UHFFFAOYSA-N 1-[5-chloro-4-[[3-[3-[[2-chloro-5-methoxy-4-[[methyl(pyrimidin-5-ylmethyl)amino]methyl]phenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-2-methoxyphenyl]-N-methyl-N-(pyrimidin-5-ylmethyl)methanamine Chemical compound CC1=C(C=CC=C1COC1=CC(=C(C=C1Cl)CN(C)CC=1C=NC=NC=1)OC)C1=C(C(=CC=C1)COC1=CC(=C(C=C1Cl)CN(CC=1C=NC=NC=1)C)OC)C VYBHXDNJGRZXKI-UHFFFAOYSA-N 0.000 claims 1
- RRVFYOSEKOTFOG-UHFFFAOYSA-N 1-phenylpropane-1,3-diol Chemical compound OCCC(O)C1=CC=CC=C1 RRVFYOSEKOTFOG-UHFFFAOYSA-N 0.000 claims 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 claims 1
- BXGYYDRIMBPOMN-UHFFFAOYSA-N 2-(hydroxymethoxy)ethoxymethanol Chemical compound OCOCCOCO BXGYYDRIMBPOMN-UHFFFAOYSA-N 0.000 claims 1
- FEQRNSWYFUNMBT-UHFFFAOYSA-N 2-[4-[3-[3-[3-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]piperazin-1-yl]ethanol Chemical compound CC1=C(C=CC=C1OCCCN1CCN(CC1)CCO)C1=C(C(=CC=C1)OCCCN1CCN(CC1)CCO)C FEQRNSWYFUNMBT-UHFFFAOYSA-N 0.000 claims 1
- UBKKNWJGYLSDSJ-UHFFFAOYSA-N 2-methylpyridine-3-carbonitrile Chemical compound CC1=NC=CC=C1C#N UBKKNWJGYLSDSJ-UHFFFAOYSA-N 0.000 claims 1
- MZQHDBUGKAFSOC-UHFFFAOYSA-N 3-(hydroxymethyl)cyclopentane-1,2-diol Chemical compound OCC1CCC(O)C1O MZQHDBUGKAFSOC-UHFFFAOYSA-N 0.000 claims 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 claims 1
- LRTIOPFTAVZGDF-UHFFFAOYSA-N 3-[3-[3-(3-aminopropoxy)-2-chlorophenyl]-2-chlorophenoxy]propan-1-amine Chemical compound ClC1=C(C=CC=C1OCCCN)C1=C(C(=CC=C1)OCCCN)Cl LRTIOPFTAVZGDF-UHFFFAOYSA-N 0.000 claims 1
- DPPKBYVYVIKDKP-DNQXCXABSA-N 3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-N-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propyl]-2-methylbenzamide Chemical compound O[C@H]1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)C(=O)NCCCN1C[C@@H](CC1)O)C)C DPPKBYVYVIKDKP-DNQXCXABSA-N 0.000 claims 1
- GENGVMRZRFNOHU-UHFFFAOYSA-N 3-[3-[3-[3-[3-(2,3-dihydroxypropylamino)propoxy]-2-methylphenyl]-2-methylphenoxy]propylamino]propane-1,2-diol Chemical compound CC1=C(C=CC=C1OCCCNCC(CO)O)C1=C(C(=CC=C1)OCCCNCC(CO)O)C GENGVMRZRFNOHU-UHFFFAOYSA-N 0.000 claims 1
- MOJOPLVNLDALBN-UHFFFAOYSA-N 3-[3-[3-[3-[3-[(2,3-dihydroxy-2-methylpropyl)amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propylamino]-2-methylpropane-1,2-diol Chemical compound CC1=C(C=CC=C1OCCCNCC(CO)(O)C)C1=C(C(=CC=C1)OCCCNCC(CO)(O)C)C MOJOPLVNLDALBN-UHFFFAOYSA-N 0.000 claims 1
- BAHOFAAZPNHRPT-UHFFFAOYSA-N 3-[3-[3-[3-[3-[2,3-dihydroxypropyl(methyl)amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl-methylamino]propane-1,2-diol Chemical compound CC1=C(C=CC=C1OCCCN(C)CC(CO)O)C1=C(C(=CC=C1)OCCCN(C)CC(CO)O)C BAHOFAAZPNHRPT-UHFFFAOYSA-N 0.000 claims 1
- WWZTVSPTWIARAF-UHFFFAOYSA-N 3-[3-[3-[3-[3-[3-hydroxypropyl(methyl)amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl-methylamino]propan-1-ol Chemical compound CC1=C(C=CC=C1OCCCN(C)CCCO)C1=C(C(=CC=C1)OCCCN(C)CCCO)C WWZTVSPTWIARAF-UHFFFAOYSA-N 0.000 claims 1
- QIZKGCRMTFTWJX-RUZDIDTESA-N 3-[[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]methyl]benzonitrile Chemical compound O[C@H]1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCC=1C=C(C#N)C=CC=1)C)C QIZKGCRMTFTWJX-RUZDIDTESA-N 0.000 claims 1
- JQCMHJACDLHSJL-LJQANCHMSA-N 3-[[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenyl]carbamoylamino]propanoic acid Chemical compound O[C@H]1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)NC(NCCC(=O)O)=O)C)C JQCMHJACDLHSJL-LJQANCHMSA-N 0.000 claims 1
- QWHDXIUUXWGQME-UHFFFAOYSA-N 3-hydroxy-4-oxobutanoic acid Chemical compound O=CC(O)CC(O)=O QWHDXIUUXWGQME-UHFFFAOYSA-N 0.000 claims 1
- CSIFGMFVGDBOQC-UHFFFAOYSA-N 3-iminobutanenitrile Chemical compound CC(=N)CC#N CSIFGMFVGDBOQC-UHFFFAOYSA-N 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- GMEAPCFBZDJCRS-CLJLJLNGSA-N N-[(3R)-1-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-yl]acetamide Chemical compound O[C@H]1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)NC(C)=O)C)C GMEAPCFBZDJCRS-CLJLJLNGSA-N 0.000 claims 1
- VVPFKRICWPTQLB-DHIUTWEWSA-N N-[2-[(3R)-3-hydroxypyrrolidin-1-yl]ethyl]-3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylbenzamide Chemical compound O[C@H]1CN(CC1)CCNC(=O)C=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C VVPFKRICWPTQLB-DHIUTWEWSA-N 0.000 claims 1
- TYUMPIQEKPMLHD-DHIUTWEWSA-N N-[2-[(3R)-3-hydroxypyrrolidin-1-yl]ethyl]-3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylbenzenesulfonamide Chemical compound O[C@H]1CN(CC1)CCNS(=O)(=O)C=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C TYUMPIQEKPMLHD-DHIUTWEWSA-N 0.000 claims 1
- MPKFZOCLDPDKFM-JOCHJYFZSA-N N-[3-(dimethylamino)propyl]-3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylbenzenesulfonamide Chemical compound CN(CCCNS(=O)(=O)C=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C)C MPKFZOCLDPDKFM-JOCHJYFZSA-N 0.000 claims 1
- MKBOKGOFMOYXHG-JWQCQUIFSA-N N-[4-[(3R)-3-hydroxypyrrolidin-1-yl]butyl]-3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylbenzamide Chemical compound O[C@H]1CN(CC1)CCCCNC(=O)C=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C MKBOKGOFMOYXHG-JWQCQUIFSA-N 0.000 claims 1
- MKFNPSFGUSMRQI-UHFFFAOYSA-N N-[[5-chloro-4-[[3-[3-[[2-chloro-5-methoxy-4-[(1H-pyrazol-5-ylmethylamino)methyl]phenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-2-methoxyphenyl]methyl]-1-(1H-pyrazol-5-yl)methanamine Chemical compound CC1=C(C=CC=C1COC1=CC(=C(C=C1Cl)CNCC1=NNC=C1)OC)C1=C(C(=CC=C1)COC1=CC(=C(C=C1Cl)CNCC1=NNC=C1)OC)C MKFNPSFGUSMRQI-UHFFFAOYSA-N 0.000 claims 1
- OOYLQBLGASEEEY-UHFFFAOYSA-N N-[[5-chloro-4-[[3-[3-[[2-chloro-5-methoxy-4-[[methyl(1H-pyrazol-5-ylmethyl)amino]methyl]phenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-2-methoxyphenyl]methyl]-N-methyl-1-(1H-pyrazol-5-yl)methanamine Chemical compound CC1=C(C=CC=C1COC1=CC(=C(C=C1Cl)CN(CC1=NNC=C1)C)OC)C1=C(C(=CC=C1)COC1=CC(=C(C=C1Cl)CN(C)CC1=NNC=C1)OC)C OOYLQBLGASEEEY-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 125000006371 dihalo methyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000004970 halomethyl group Chemical group 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- QAABAIHPYHVVMQ-UHFFFAOYSA-N n-(2-pyridin-4-ylethyl)propan-1-amine Chemical compound CCCNCCC1=CC=NC=C1 QAABAIHPYHVVMQ-UHFFFAOYSA-N 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000001301 oxygen Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- IZXWMVPZODQBRB-UHFFFAOYSA-N piperidine-3,4-diol Chemical compound OC1CCNCC1O IZXWMVPZODQBRB-UHFFFAOYSA-N 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229910052717 sulfur Chemical group 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 125000004953 trihalomethyl group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382480P | 2016-09-01 | 2016-09-01 | |
| US62/382,480 | 2016-09-01 | ||
| US15/689,115 US10144706B2 (en) | 2016-09-01 | 2017-08-29 | Compounds useful as immunomodulators |
| US15/689,115 | 2017-08-29 | ||
| PCT/US2017/049252 WO2018044963A1 (en) | 2016-09-01 | 2017-08-30 | Biaryl compounds useful as immunomodulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531274A JP2019531274A (ja) | 2019-10-31 |
| JP2019531274A5 true JP2019531274A5 (enExample) | 2020-10-08 |
| JP7155110B2 JP7155110B2 (ja) | 2022-10-18 |
Family
ID=61241693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511947A Active JP7155110B2 (ja) | 2016-09-01 | 2017-08-30 | 免疫調節剤として有用なビアリール化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10144706B2 (enExample) |
| EP (1) | EP3507284B1 (enExample) |
| JP (1) | JP7155110B2 (enExample) |
| KR (1) | KR102497068B1 (enExample) |
| CN (1) | CN109863146B (enExample) |
| AR (1) | AR109471A1 (enExample) |
| AU (1) | AU2017319323A1 (enExample) |
| BR (1) | BR112019004100A2 (enExample) |
| CA (1) | CA3035697A1 (enExample) |
| EA (1) | EA201990495A1 (enExample) |
| ES (1) | ES2919298T3 (enExample) |
| MA (1) | MA46091A (enExample) |
| MX (1) | MX2019002356A (enExample) |
| SG (1) | SG11201901700UA (enExample) |
| TW (1) | TW201815764A (enExample) |
| WO (1) | WO2018044963A1 (enExample) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| EP3474845B1 (en) | 2016-06-27 | 2024-03-20 | ChemoCentryx, Inc. | Immunomodulator compounds |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| WO2018118848A1 (en) | 2016-12-20 | 2018-06-28 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| JP6971319B2 (ja) | 2016-12-28 | 2021-11-24 | グリーン・クロス・ラブ・セル・コーポレイション | キメラ抗原受容体及びそれを発現するナチュラルキラー細胞 |
| CN108250159B (zh) * | 2016-12-29 | 2023-07-11 | 深圳微芯生物科技股份有限公司 | 脲类化合物、其制备方法及其应用 |
| CN110461829B (zh) | 2017-03-27 | 2023-02-28 | 百时美施贵宝公司 | 作为免疫调节剂的取代的异喹啉衍生物 |
| JOP20180040A1 (ar) * | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| WO2018200571A1 (en) | 2017-04-25 | 2018-11-01 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1h-indene analogs and methods using same |
| WO2019008156A1 (en) * | 2017-07-07 | 2019-01-10 | Rijksuniversiteit Groningen | INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1 |
| IL272258B (en) | 2017-07-28 | 2022-08-01 | Chemocentryx Inc | Immunomodulator compounds |
| EP3664793B1 (en) | 2017-08-08 | 2022-06-29 | ChemoCentryx, Inc. | Macrocyclic immunomodulators |
| EP3712178A4 (en) | 2017-11-14 | 2021-08-11 | Green Cross Lab Cell Corporation | ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| KR102738303B1 (ko) | 2018-01-23 | 2024-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제로서 유용한 2,8-디아실-2,8-디아자스피로[5.5]운데칸 화합물 |
| JP7062792B2 (ja) | 2018-02-13 | 2022-05-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| US10568874B2 (en) | 2018-02-22 | 2020-02-25 | Chemocentryx, Inc. | Indane-amines as PD-L1 antagonists |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| CN112041312A (zh) | 2018-03-01 | 2020-12-04 | 百时美施贵宝公司 | 用作免疫调节剂的化合物 |
| CA3093851A1 (en) * | 2018-03-29 | 2019-10-03 | Arbutus Biopharma Corporation | Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| EP3781556B1 (en) * | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| TW202017569A (zh) | 2018-05-31 | 2020-05-16 | 美商佩樂敦治療公司 | 用於抑制cd73之組合物及方法 |
| WO2020011246A1 (zh) * | 2018-07-13 | 2020-01-16 | 广州丹康医药生物有限公司 | 含苯环的化合物、其制备方法及应用 |
| CN118221646A (zh) | 2018-07-13 | 2024-06-21 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| TWI826492B (zh) | 2018-07-27 | 2023-12-21 | 加拿大商愛彼特生物製藥公司 | 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| CN109305934A (zh) * | 2018-08-07 | 2019-02-05 | 成都海博锐药业有限公司 | 苯醚类衍生物及可药用盐、医药上的用途 |
| CN110872275A (zh) * | 2018-08-31 | 2020-03-10 | 深圳微芯生物科技股份有限公司 | 作为免疫调节剂的联苯化合物及其用途 |
| KR102635333B1 (ko) * | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| SG11202105850YA (en) | 2018-11-02 | 2021-07-29 | Shanghai Maxinovel Pharmaceuticals Co Ltd | Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof |
| TWI827760B (zh) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
| WO2020144332A1 (en) * | 2019-01-11 | 2020-07-16 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Fusion protein with immunosuppressive activity |
| AU2020231115B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
| US20220195046A1 (en) | 2019-03-28 | 2022-06-23 | Bristol-Myers Squibb Company | Methods of treating tumor |
| US20220041733A1 (en) | 2019-03-28 | 2022-02-10 | Bristol-Myers Squibb Company | Methods of treating tumor |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| MA55974A (fr) | 2019-05-15 | 2022-03-23 | Chemocentryx Inc | Composés triaryles pour le traitement de maladies pd-l1 |
| US20220251141A1 (en) * | 2019-05-21 | 2022-08-11 | Bristol-Myers Squibb Company | Immunomodulators |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| JP2022534982A (ja) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 細胞局在化シグネチャーおよびその使用 |
| WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| WO2020244518A1 (zh) * | 2019-06-04 | 2020-12-10 | 中国科学院上海药物研究所 | 一种具有苄氧基芳环结构的化合物，其制备方法和用途 |
| CA3139242A1 (en) | 2019-06-20 | 2020-12-24 | Viengkham Malathong | Compounds for treatment of pd-l1 diseases |
| CA3145303A1 (en) | 2019-07-10 | 2021-01-14 | Chemocentryx, Inc. | Indanes as pd-l1 inhibitors |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN111909108B (zh) * | 2019-09-02 | 2023-05-02 | 中国药科大学 | 联苯类化合物及其制备方法和医药用途 |
| WO2021055994A1 (en) | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
| EP4458975A3 (en) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| US20240124417A1 (en) * | 2019-10-04 | 2024-04-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| EP4045037A4 (en) | 2019-10-16 | 2023-11-15 | ChemoCentryx, Inc. | HETEROARYL-BIPHENYL AMINE FOR THE TREATMENT OF PD-L1 DISEASE |
| EP4045036A4 (en) | 2019-10-16 | 2023-11-15 | ChemoCentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases |
| US20220411499A1 (en) | 2019-11-08 | 2022-12-29 | Bristol-Myers Squibb Company | LAG-3 Antagonist Therapy for Melanoma |
| EP4069729B1 (en) | 2019-12-06 | 2025-01-22 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| KR20230041654A (ko) | 2020-05-05 | 2023-03-24 | 테온 테라퓨틱스, 인크. | 칸나비노이드 수용체 유형 2 (cb2) 조정제 및 그의 용도 |
| CA3193421A1 (en) | 2020-08-28 | 2022-03-03 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
| EP4204453A1 (en) | 2020-08-31 | 2023-07-05 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| US20230331675A1 (en) | 2020-09-09 | 2023-10-19 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Aromatic ethylene compound and preparation method therefor, and intermediate, pharmaceutical composition, and application thereof |
| KR20230066582A (ko) | 2020-09-10 | 2023-05-16 | 남미 테라퓨틱스, 인크. | 암의 치료에 유용한 pd-1 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법 |
| EP4232019A1 (en) | 2020-10-23 | 2023-08-30 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| KR20240005700A (ko) | 2021-03-29 | 2024-01-12 | 주노 쎄러퓨티크스 인코퍼레이티드 | 체크포인트 억제제 요법 및 car t 세포 요법의 조합을 사용한 투여 및 치료 방법 |
| CN113135895A (zh) * | 2021-04-30 | 2021-07-20 | 中国药科大学 | 一种新型联苯类衍生物及其制备方法与医药用途 |
| AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| CN117651554A (zh) | 2021-06-11 | 2024-03-05 | 吉利德科学公司 | Mcl-1抑制剂与抗癌剂的组合 |
| WO2022261310A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN115677665B (zh) * | 2021-07-26 | 2024-04-19 | 中国药科大学 | 含联苯类衍生物及其医药用途 |
| WO2023034530A1 (en) | 2021-09-02 | 2023-03-09 | Teon Therapeutics, Inc. | Methods of improving growth and function of immune cells |
| WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| WO2023081730A1 (en) | 2021-11-03 | 2023-05-11 | Teon Therapeutics, Inc. | 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer |
| WO2023097211A1 (en) | 2021-11-24 | 2023-06-01 | The University Of Southern California | Methods for enhancing immune checkpoint inhibitor therapy |
| JP2025503962A (ja) | 2022-01-26 | 2025-02-06 | ブリストル－マイヤーズ スクイブ カンパニー | 肝細胞がんのための併用療法 |
| IL315992A (en) | 2022-04-08 | 2024-11-01 | Bristol Myers Squibb Co | Identification, classification and quantification of tertiary lymphoid structures using machine learning |
| WO2024015372A1 (en) | 2022-07-14 | 2024-01-18 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
| AU2023409221A1 (en) | 2022-12-21 | 2025-06-12 | Bristol-Myers Squibb Company | Combination therapy for lung cancer |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU75628A1 (enExample) * | 1976-08-19 | 1978-04-13 | ||
| CH654286A5 (de) * | 1981-11-04 | 1986-02-14 | Ciba Geigy Ag | Verfahren zur pd-katalysierten arylierung von olefinen mit arylhalogeniden. |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5977117A (en) | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| JPWO2004007439A1 (ja) | 2002-07-10 | 2005-11-10 | 住友製薬株式会社 | ビアリール誘導体 |
| US7741352B2 (en) | 2003-03-11 | 2010-06-22 | Neurosearch A/S | KCNQ channel modulating compounds and their pharmaceutical use |
| JP2005179281A (ja) | 2003-12-19 | 2005-07-07 | Sumitomo Pharmaceut Co Ltd | ビフェニル化合物 |
| EP1723132A1 (en) | 2004-02-12 | 2006-11-22 | Asterand Uk Limited | Ep2 receptor agonists |
| EP1717235A3 (en) | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
| CA2618486A1 (en) | 2005-08-09 | 2007-02-15 | Asterand Uk Limited | Ep2 receptor agonists |
| TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| WO2008130514A1 (en) | 2007-04-16 | 2008-10-30 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
| TW200932219A (en) | 2007-10-24 | 2009-08-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| TWI444467B (zh) | 2010-05-27 | 2014-07-11 | Angus Chemical | 用於液體碳氫化合物及其他燃料與油之標記物化合物 |
| EA029901B1 (ru) * | 2013-09-04 | 2018-05-31 | Бристол-Майерс Сквибб Компани | Соединения для применения в качестве иммуномодуляторов |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| BR112017025768A2 (pt) * | 2015-06-29 | 2018-08-14 | Univ Vanderbilt | administração intravenosa de citrulina durante cirurgia |
| US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| CN109689640B (zh) | 2016-07-08 | 2022-01-04 | 百时美施贵宝公司 | 可用作免疫调节剂的化合物 |
| WO2018026971A1 (en) | 2016-08-03 | 2018-02-08 | Arising International, Llc | Symmetric or semi-symmetric compounds useful as immunomodulators |
-
2017
- 2017-08-29 US US15/689,115 patent/US10144706B2/en active Active
- 2017-08-30 BR BR112019004100A patent/BR112019004100A2/pt not_active Application Discontinuation
- 2017-08-30 MA MA046091A patent/MA46091A/fr unknown
- 2017-08-30 EA EA201990495A patent/EA201990495A1/ru unknown
- 2017-08-30 WO PCT/US2017/049252 patent/WO2018044963A1/en not_active Ceased
- 2017-08-30 SG SG11201901700UA patent/SG11201901700UA/en unknown
- 2017-08-30 CN CN201780067319.8A patent/CN109863146B/zh active Active
- 2017-08-30 KR KR1020197008795A patent/KR102497068B1/ko active Active
- 2017-08-30 TW TW106129492A patent/TW201815764A/zh unknown
- 2017-08-30 MX MX2019002356A patent/MX2019002356A/es unknown
- 2017-08-30 JP JP2019511947A patent/JP7155110B2/ja active Active
- 2017-08-30 CA CA3035697A patent/CA3035697A1/en not_active Abandoned
- 2017-08-30 ES ES17764981T patent/ES2919298T3/es active Active
- 2017-08-30 AR ARP170102407A patent/AR109471A1/es unknown
- 2017-08-30 AU AU2017319323A patent/AU2017319323A1/en not_active Abandoned
- 2017-08-30 EP EP17764981.1A patent/EP3507284B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531274A5 (enExample) | ||
| JP7609854B2 (ja) | Ｍａｇｌ阻害剤としての４，４ａ，５，７，８，８ａ－ヘキサピリド［４，３－ｂ］［１，４］オキサジン－３－オン化合物 | |
| US8778951B2 (en) | Heteroaryl compounds and their uses | |
| ES2942319T3 (es) | Inhibidores de oxacina monoacilglicerol lipasa (MAGL) | |
| US9085540B2 (en) | Pyrazinecarboxamide compound | |
| US10080750B2 (en) | Aminopyrimidine derivatives for use as modulators of kinase activity | |
| US10751332B2 (en) | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | |
| TWI583670B (zh) | Partially saturated nitrogenous heterocyclic compounds | |
| US20120157433A1 (en) | Heteroaryl Compounds as Kinase Inhibitors | |
| RU2016137674A (ru) | Производные пиперидиндиона | |
| US20130303507A1 (en) | Substituted hetero-biaryl compounds and their uses | |
| EA032609B1 (ru) | Соединения аминопиримидинила в качестве ингибиторов jak | |
| US20120165306A1 (en) | Pyrazinylpyridines useful for the treatment of proliferative diseases | |
| HK1046866A1 (zh) | 3(5)-氨基-吡唑衍生物、其制备方法及其用作抗肿瘤剂的用途 | |
| US20110130380A1 (en) | Heteroaryl Kinase Inhibitors | |
| WO2012101065A2 (en) | Pyrimidine biaryl amine compounds and their uses | |
| JP6454418B2 (ja) | ピラゾール誘導体、またはその薬理学的に許容される塩 | |
| JP7114591B2 (ja) | Ｇｓｋ－３阻害剤 | |
| US20190060282A1 (en) | Imidazolylamide derivative | |
| WO2015012400A1 (ja) | グリシントランスポーター阻害物質 | |
| WO2015163472A1 (ja) | トリアゾリルで置換されたヘテロアリール化合物 | |
| JP6569678B2 (ja) | ２−アミノチアゾール誘導体またはその塩 | |
| HK40062310A (en) | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |